- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A GP complained about an allegedly unsolicited visit and disparaging comments about Symbicort SMART prescribing. Accounts conflicted and the Panel could not…
Otsuka Europe misclassified a promotional congress symposium as non-promotional (disguised promotion) and a senior employee’s internal comments were found to undermine whistleblowing…
Anonymous ex-employee alleged UK doctors were invited to a “lavish” Berlin meeting based on prescribing and that hospitality/entertainment breached the Code. Panel…
Complaint upheld in part: Dr Falk Pharma’s HCP website pages (and a linked historical ad) lacked compliant prescribing information; a Jorveza media…
Mitsubishi Tanabe’s corporate products pages for Exembol (argatroban) and Tanatril were accessible to the public and included product claims/indications without clear audience…
Takeda’s homepage headline “NICE says no to life saving treatment…” linked to a Mepact press release with emotive survival claims. PMCPA ruled…
Novo Nordisk challenged a Janumet e-detail headline and a prominent 1.8% HbA1c subgroup result. PMCPA ruled the headline was a hanging comparison,…
Shire challenged Norgine’s ‘NICE recommends MOVICOL Paediatric Plain FIRST-LINE’ ad/leavepiece as unauthorised, unreferenced and implying off-label paediatric use. PMCPA ruled no breach…
Anonymous complaint alleged reps used litmus paper and eye drops to demonstrate pH and encouraged instillation into eyes. Panel found no evidence…
BMJ analysis suggested Roche had 15 due EUCTR trials without posted results. Panel found 14 had no UK nexus and 1 UK-site…
A GP complained about a Daily Mail article on Pradaxa. PMCPA assessed BI’s press release (not the article) and ruled it breached…
Shire’s VPRIV website was ruled misleading for “at least as effective as” (non-inferiority data), “does not require gene manipulation”, and “minimising the…
PMCPA case AUTH/3117/11/18 (Director v Seqirus) concerned clinical trial disclosure but was ruled outwith the scope of the ABPI Code (2016). No…
BMJ analysis suggested Teva had unreported EUCTR trial results (72% disclosed). Panel initially found Clause 9.1 breaches for two UK-nexus trials, but…
Merz’s Bocouture ad in Cosmetic News implied 1:1 clinical conversion/equal potency vs Botox. PMCPA ruled it breached a prior undertaking and failed…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.